Morphosys AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider : Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Morphosys AG receives additional patents on novel antibody platform Ylanthia in the U.S. and first patent in China
Morphosys AG:Announces that the U.S. Patent and Trademark Office (USPTO) and the State Intellectual Property Office of China have granted additional patents covering the company's latest antibody platform Ylanthia.
Latest Developments forMorphosys AG
- Share this
- Digg this